DRF-1042,200619-13-2

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

DRF-1042

CAS No. : 200619-13-2

MCE 国际站：DRF-1042

产品活性：DRF-1042 是一种具有口服活性的喜树碱类似物，具有抑制 DNA 拓扑异构酶 I (DNA topoisomerase I) 的作用。DRF-1042 对一组人癌细胞株，包括多药耐药 (MDR)表型，显示出良好的抗癌活性。

研究领域：Cell Cycle/DNA Damage  |  Antibody-drug Conjugate/ADC Related

作用靶点：Topoisomerase  |  ADC Cytotoxin

In Vitro: DRF-1042 demonstrates superior lactone stability and good in vitro anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype.

In Vivo: In clonogenic assay against murine, canine and human bone marrow cells, DRF-1042 treatment shows less mylosupression that supports the possibility of protracted dose schedule in both experimental and clinical studies.

相关产品：Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Toxins for Antibody-Drug Conjugate Research Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Orally Active Compound Library  |  Anti-Lung Cancer Compound Library  |  Heterocyclic Compound Library  |  Doxorubicin hydrochloride  |  Paclitaxel  |  Etoposide  |  Monomethyl auristatin E  |  Exatecan mesylate  |  Mitomycin C  |  Methotrexate  |  SN-38  |  Irinotecan  |  Camptothecin  |  Topotecan hydrochloride  |  Mertansine  |  Daunorubicin hydrochloride  |  α-Amanitin  |  Mitoxantrone  |  Berberine chloride  |  Epirubicin hydrochloride  |  MMAF  |  Exatecan Intermediate 1  |  Ciprofloxacin  |  Levofloxacin  |  Betulinic acid  |  EIDD-1931  |  DM4  |  Suramin sodium salt  |  Calicheamicin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds